您的位置：山东大学 -> 科技期刊社 -> 《山东大学学报（医学版）》

山东大学学报（医学版） ›› 2016, Vol. 54 ›› Issue (5): 79-83.doi: 10.6040/j.issn.1671-7554.0.2015.1144

• • 上一篇    下一篇

养正消积胶囊联合化疗治疗转移性乳腺癌的临床疗效及安全性

徐志宏1,刘荣凤1,王晓翔1,冯莉1,姚铁柱2,刘红3   

  1. 河北医科大学第四医院 1.肿瘤内科;2.心内科;3.妇瘤科, 河北 石家庄 050011
  • 收稿日期:2015-11-20 出版日期:2016-05-16 发布日期:2016-05-16
  • 通讯作者: 姚铁柱. E-mail:13733315579 @163.com E-mail:13733315579 @163.com

Efficacy and safety of Yangzheng Xiaoji capsule combined with chemotherapy in treating metastatic breast cancer

XU Zhihong1, LIU Rongfeng1, WANG Xiaoxiang1, FENG Li1, YAO Tiezhu2, LIU Hong3   

  1. 1. Department of Oncology;
    2. Department of Cardiology;
    3. Department of Gynecological Tumor, Fourth Hospital of Hebei Medical University, Shijiazhuang 050011, Hebei, China
  • Received:2015-11-20 Online:2016-05-16 Published:2016-05-16

PDF (PC)

347

摘要： 目的 探讨养正消积胶囊联合化疗治疗转移性乳腺癌的有效性和安全性以及对T淋巴细胞亚群的影响。 方法 将转移性乳腺癌79例患者按随机数字表法分为治疗组(40例)和对照组(39例);对照组给予GT化疗方案治疗,21d/周期,共6个周期;治疗组在对照组基础上口服养正消积胶囊,化疗第1天开始给予,4粒/次,3次/d,连续服用,21d/周期,共6个周期。比较两组临床疗效和不良反应;参照生活质量问卷-乳腺癌模式量表(QLQ-BR23)分析两组生存质量;检测两组血清T 淋巴细胞亚群水平。 结果 治疗组总有效率为55%,明显高于对照组的28.21%(P<0.05);治疗组肝肾功能不全发生率为10%,明显低于对照组的33.33%(P<0.05);治疗后6个月,治疗组患者的体型和未来看法评分均明显高于对照组,而性功能、性乐趣、乳房症状、脱发引起的烦恼、手臂症状以及系统治疗不良反应评分均低于对照组(P<0.01);治疗后3个月,治疗组CD3+、CD4+、CD4+/CD8+水平均明显高于治疗前和对照组同期水平,而CD8+水平明显降低(P<0.01)。 结论 养正消积胶囊联合化疗治疗转移性乳腺癌的疗效确切,安全性高,且可明显改善患者生活质量及提高细胞免疫功能。

关键词: 转移性乳腺癌, 联合化疗, T淋巴细胞亚群, 养正消积胶囊

Abstract: Objective To investigate the efficacy and safety of Yangzheng Xiaoji capsule combined with chemotherapy in the treatment of metastatic breast cancer and its influence on T lymphocyte cell subsets. Methods A total of 79 metastatic breast cancer patients were randomly divided into the treatment group(n=40)and control group(n=39)according to digital table method. The control group was treated with GT chemotherapy, which was a total of 6 courses of treatment with q3w. The treatment group received the same amount of chemotherapy, and Yangzheng Xiaoji capsules, 4 capsules/time, 3 times/day, 21 days/course, for 6 courses of treatment. The clinical efficacy and adverse reactions were compared between the two groups. The survival quality of all patients was analyzed by QLQ-BR23. T sublymphocyte level was detected in both groups. Results The total efficacy rate of the treatment group was 55%, which was superior to that of the control group, 28.21%(P<0.05). Incidence of liver and kidney function deficiency in the treatment group was 10%, which was lower than that of the control group, 33.33%(P<0.05). Six months after treatment, scores of QLQ-BR23 in the treatment group were superior to those of the control group(P<0.01). Three months after treatment, levels of CD3+, CD4+ and CD4+/CD8+ of the treatment group were higher than those of the control group, while CD8+ was lower, with statistically significant difference(P<0.01). Conclusion Yangzheng 山 东 大 学 学 报 (医 学 版)54卷5期 -徐志宏,等.养正消积胶囊联合化疗治疗转移性乳腺癌的临床疗效及安全性 \=-Xiaoji capsule combined with chemotherapy in treating metastatic breast cancer can increase efficacy, decrease adverse reactions, and improve quality of life and cellular immune function.

Key words: Yangzheng Xiaoji capsule, Metastatic breast cancer, Combined chemotherapy, T lymphocyte cell subsets

中图分类号: 

  • R737.9
[1] 陆永奎, 谢伟敏, 周文献, 等. 重组人血管内皮抑制素联合全身化疗治疗转移性乳腺癌的临床疗效观察[J]. 重庆医学, 2013, 42(18): 2074-2079. LU Yongkui, XIE Weimin, ZHOU Wenxian, et al. Clinical observation of Rh-endostatin combined with chemotherapy for metastatic breast cancer[J]. Chongqing Medicine, 2013, 42(18): 2074-2079.
[2] 王志光, 向培, 范先基, 等. 穴位埋线在GT方案治疗转移性乳腺癌中的应用[J]. 广东医学, 2013, 34(6): 959-962.
[3] 章巧琪, 万冬桂. 转移性乳腺癌的中医治疗现状[J]. 北京中医药大学学报(中医临床版), 2011, 18(4): 43-45.
[4] 张莹, 贾英杰, 陈军, 等.养正消积胶囊联合昂丹司琼预防乳腺癌化疗所致恶心呕吐的疗效[J]. 中国老年学杂志, 2012, 32(24): 5524-5525.
[5] 沈镇宙, 邵志敏. 乳腺肿瘤学[M]. 上海: 上海科学技术出版社, 2005: 1.
[6] Wan C, Tang X, Tu XM, et al. Psychometric properties of the simplified Chinese version of the EORTC QLQ-BR53 for measuring quality of life for breast cancer patients[J]. Breast Cancer Res Treat, 2007, 105(2): 187-193.
[7] Elisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline(version 1.1)[J]. Eur J Cancer, 2009, 45(2): 228-247.
[8] Lee WH, Liu HE, Chang JY, et al. MPT0B169, a new tubulin inhibitor, inhibits cell growth and induces G2/M arrest in nonresistant and paclitaxel-resistant cancer cells[J]. Pharmacology, 2013, 92(1-2): 90-98.
[9] Leitner S, Sweeney K, Oberg D, et al. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo[J]. Clin Cancer Res, 2009, 15(5): 1730-1740.
[10] Xu B, Zhang XQ, Chi HD, et al. Consistent efficacy and safety of gemcitabine-paclitaxel in patients with metastatic breast cancer: a retrospective comparison of East Asian and global studies[J]. Asia Pac J Clin Oncol, 2014, 10(4): 330-339.
[11] Vici P, Giotta F, Di Lauro L, et al. A multicenter phaseⅡrandomized trial of docetaxel/ gemcitabine versus docetaxel/ capecitabine as first-line treatment for advanced breast cancer: a gruppo oncologico italia meridionale study[J]. Oncology, 2011, 81(3-4): 230-236.
[12] 张振华. 吉西他滨联合多西紫杉醇治疗复发转移性乳腺癌疗效分析[J]. 肿瘤基础与临床, 2013, 26(6): 488-489. ZHANG Zhenhua. Efficacy of gemcitabine plus docetaxel in the treatment of recurrent metastatic breast cancer[J]. Journal of Basicand Clinicai Oncology, 2013, 26(6): 488-489.
[13] Holoubková E, Skrivanová K, Nedvěd J, et al. Methods of assessing quality of life in women with breast cancer-overview and basic characteristics[J]. Klin Onkol, 2015, 28(5): 332-337.
[14] Motyka M, Dziubak M, Patrycja J. The sense of coherence and the quality of life of patients treated for breast cancer[J]. Przegl Lek, 2014, 71(5): 270-273.
[15] Jiang X. Harnessing the immune system for the treatment of breast cancer[J]. J Zhejiang Univ Sci B, 2014,15(1):1-15.
[16] 白海亚, 马秀芬. 新辅助化疗对局部进展期乳腺癌患者T淋巴细胞亚群及NK细胞免疫功能的影响[J]. 中国免疫学杂志, 2012, 9(28): 843-845. BAI Haiya, MA Xiufen. T lymphocyte subsets immunity and NK cells in patients with locally advanced breast cancer submitted to neoadjuvant chemotherapy[J]. Chinese Journal of Immunology, 2012, 9(28): 843-845.
[17] 张剑, 吴敏, 张自森, 等. 养正消积胶囊对原发性肝癌肝动脉化疗栓塞术后患者细胞免疫功能及血管形成的影响[J]. 中国实验方剂学杂志, 2014, 20(13): 189-192. ZHANG Jian, WU Min, ZHANG Zisen, et al. Influence of Yangzheng Xiaoji capsule cellular immune function and angiogenesis in treating primary liver cancer after arterial chemoembolization[J]. Chinese Journal of Experimental Traditional Medical Formulae, 2014, 20(13): 189-192.
[1] 徐统震，孙雪飞，任冬梅，杨国涛. 木犀草素抑制肺癌细胞A549的增殖及其联合化疗作用[J]. 山东大学学报(医学版), 2012, 50(7): 50-54.
[2] 吴艳，惠复新，赵寅滢，范晓东，卞涛. 慢性阻塞性肺疾病患者病毒感染状况及与T淋巴细胞免疫功能的关系[J]. 山东大学学报(医学版), 2011, 49(11): 117-.
[3] 李振峰,李建民,杨志平,李昕. 胫骨近段骨肉瘤的切除和功能重建[J]. 山东大学学报(医学版), 2007, 45(3): 322-322.
[4] 王玮,孙文辉,鲁露. 泰素帝联合吉西他宾治疗晚期非小细胞肺癌30例临床观察[J]. 山东大学学报(医学版), 2007, 45(12): 1233-1233.
[5] 张维东,张月英,王朝霞,贾青,王兆朋,于金明 . 柞蚕雄蛾提取液改善W256荷瘤大鼠放疗后免疫功能的实验研究[J]. 山东大学学报(医学版), 2007, 45(11): 1085-1087.
Viewed
Full text


Abstract

Cited
  Shared   
  Discussed   
No Suggested Reading articles found!
版权所有 © 2018 《山东大学学报(医学版)》编辑部　
地址:山东大学科技期刊社（济南市历城区山大南路27号山东大学中心校区明德楼B座721室） 电话: 0531-88366918 E-mail: xbyxb@sdu.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发